Global Alzheimer’s Platform Foundation Announces GAP-Net

First-of-its-Kind Network of Clinical Trial Sites Quickens Timeline and Quality of Alzheimer’s Clinical Trials

WASHINGTON, D.C. – The Global Alzheimer’s Platform Foundation (GAP) announced the launch of GAP-Net, a first-of-its-kind network of clinical trial sites collaboratively working to streamline clinical research and drug development for Alzheimer’s disease. GAP-Net currently has 11 leading academic and private commercial research site partners. The network looks to add a minimum of 20 more sites by year-end and grow to 60 sites nationally by the end of 2017.

Read the full release here.